Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509362 | 1.00 | CTSS (0.48) | CTSSCTSKKLK5DPP4TACR1 | |
| SCHEMBL29919743 | 0.91 | CTSS (0.46) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL19667910 | 0.90 | AAK1 (0.46) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL1509650 | 0.90 | AAK1 (0.46) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL17068953 | 0.90 | CTSS (0.47) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL17068956 | 0.90 | CTSS (0.47) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL5878185 | 0.89 | MTNR1A (0.54) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL6317580 | 0.89 | MTNR1A (0.54) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL6317579 | 0.89 | MTNR1A (0.54) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL1509374 | 0.88 | PTPN1 (0.53) | CTSSCTSKDPP4PTPN1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4539844-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245166-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CTSS 29/4885CTSK 123/4885KLK5 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.